[EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
申请人:CEPHALON INC
公开号:WO2010071885A1
公开(公告)日:2010-06-24
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
Cyclic urea derivatives, pharmaceutical compositions containing these
申请人:Karl Thomae GmbH
公开号:US05681841A1
公开(公告)日:1997-10-28
The invention relates to cyclic urea derivatives of general formula I ##STR1## wherein R.sub.a, R.sub.b, X and Y are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation inhibiting effects, and to drugs containing the compounds and processes for preparing them.
COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
申请人:Hart Terance William
公开号:US20090048230A1
公开(公告)日:2009-02-19
The present invention relates to the use of a 2-cyanopyrimidine compound of the formula
wherein
R
1
, R
2
, R
3
and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
The present invention provides a compound of formula I
or a salt form thereof, wherein Q
1
, Q
2
, Q
3
, and Q
4
are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
The present invention provides a compound of formula I
or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.